Ivermectin is best known as an antiparasitic drug that changed global health outcomes for millions of people. Since its introduction in the 1980s, it has been used to treat river blindness (onchocerciasis), lymphatic filariasis, and strongyloidiasis across dozens of countries. The scientists behind its development received the 2015 Nobel Prize in Physiology or Medicine for their contributions to parasitic disease control.
In recent years, however, researchers have begun asking a different question: could ivermectin play a role in cancer treatment — particularly when combined with immunotherapy? This article provides an evidence-based overview of what we know, what is being studied, and where the science currently stands.
What Is Ivermectin?
Ivermectin is a broad-spectrum antiparasitic agent originally derived from the bacterium Streptomyces avermitilis. It was developed in the late 1970s and has since become one of the most widely used antiparasitic medications in the world. It is included on the WHO Model List of Essential Medicines and has been administered billions of times globally.
Because ivermectin is off-patent, inexpensive, widely available, and has a well-characterized safety profile at approved doses, it has attracted interest as a candidate for drug repurposing — the practice of investigating established medications for potential new therapeutic applications, including oncology.
If you want a broader overview of ivermectin’s medical uses and safety profile, see our detailed article: Ivermectin: What It Is, How It Works, and Why It’s Used.
Why Researchers Are Investigating Ivermectin in Oncology
The interest in ivermectin’s potential anticancer properties is not based on speculation — it comes from a growing body of preclinical research (laboratory and animal studies) suggesting the drug may affect multiple biological pathways relevant to tumor biology. These findings, while still early-stage, have been published in peer-reviewed journals and are driving further investigation.
Proposed Mechanisms of Action in Cancer
Several molecular and cellular mechanisms have been identified in laboratory settings:
- Inhibition of proliferation pathways: Ivermectin has been shown to interfere with PAK1 kinase and WNT-TCF signaling, both of which are involved in tumor cell growth and metastasis. A 2020 review in Pharmacological Research documented these and other anti-tumor mechanisms across multiple cancer cell lines (PMC7505114).
- Induction of apoptosis: Studies have observed that ivermectin can trigger programmed cell death through mitochondrial dysfunction and reactive oxygen species (ROS) generation in various cancer models.
- Effects on cancer stem cells: Some research suggests ivermectin may target cancer stem-like cells, which are thought to drive treatment resistance and recurrence.
- Modulation of the tumor microenvironment: Preclinical data indicate ivermectin may influence immune cell infiltration and reduce immunosuppressive signaling within tumors, potentially making them more responsive to immune-based therapies.
- Immunogenic cell death (ICD): A 2021 study published in Frontiers in Pharmacology found that ivermectin induced immunogenic cell death markers in breast cancer models, suggesting it could prime the immune system to recognize tumor cells (PMC8419571).
Important Context
These findings come primarily from in vitro (cell culture) and in vivo (animal) experiments. Preclinical results do not automatically translate into clinical effectiveness in humans. Concentrations used in laboratory settings often exceed what is achievable with standard oral dosing. This is precisely why clinical trials are essential to determine real-world safety and efficacy.
Ivermectin and Immunotherapy: The Combination Hypothesis
One of the most active areas of investigation is whether ivermectin can enhance the effectiveness of immune checkpoint inhibitors (ICIs) — drugs like pembrolizumab and balstilimab that work by removing the “brakes” on the immune system so it can attack cancer cells more effectively.
The rationale for combining ivermectin with immunotherapy rests on several preclinical observations:
- Ivermectin may help convert immunologically “cold” tumors (those that evade immune detection) into “hot” tumors (those that attract immune cells).
- By inducing immunogenic cell death, ivermectin could release tumor-associated antigens that prime T-cell responses.
- Ivermectin’s effects on the tumor microenvironment may reduce immunosuppressive factors like regulatory T cells and myeloid-derived suppressor cells.
These mechanisms suggest ivermectin could act as an immunotherapy sensitizer — not replacing checkpoint inhibitors, but potentially improving their effectiveness. This hypothesis is now being tested in humans.
Clinical Trial: Ivermectin + Immunotherapy in Metastatic TNBC (NCT05318469)
Triple-negative breast cancer (TNBC) is one of the most aggressive breast cancer subtypes and has limited treatment options, especially for patients who progress after initial therapy. Even with advances in immune checkpoint inhibitors, response rates in pretreated metastatic TNBC remain modest.
An ongoing Phase I/II clinical trial (NCT05318469) at Cedars-Sinai Medical Center in Los Angeles is evaluating the combination of oral ivermectin with either balstilimab or pembrolizumab in patients with metastatic TNBC. This is one of the first structured human studies to formally test ivermectin as an immunotherapy adjunct in a solid tumor setting.
Trial Design Overview
| Parameter | Details |
|---|---|
| Trial ID | NCT05318469 |
| Phase | I/II, single-arm, open-label |
| Enrollment | 34 adults with metastatic TNBC |
| Location | Cedars-Sinai Medical Center, Los Angeles |
| Start Date | October 2023 |
| Est. Completion | October 2026 |
Treatment Protocol
Each treatment cycle lasts 21 days. Within each cycle:
- Ivermectin (oral): Days 1–3, 8–10, and 15–17
- Balstilimab (450 mg IV) or Pembrolizumab (200 mg IV): Day 1 of each cycle
- Treatment continues for up to 35 cycles (~2 years) or until disease progression, unacceptable toxicity, or patient withdrawal
The primary objectives are to assess safety, tolerability, and identify the recommended Phase II dose. Secondary endpoints include objective response rate, disease control rate, and pharmacokinetic interactions between ivermectin and the immunotherapy agents.
For a deeper analysis of this trial’s design, schedule, and implications, see our dedicated article: Inside Trial NCT05318469: Can Ivermectin Enhance Immunotherapy?
Products Referenced in This Article
Pharmaceutical-grade ivermectin referenced in the immunotherapy research above.
6 / 12 / 18 mg — 100 tablets
Disclaimer: For convenience only. Consult a licensed professional.
What About Other Cancer Types?
While the Cedars-Sinai trial focuses on TNBC, preclinical research has explored ivermectin’s effects across a range of cancer types, including:
- Colorectal cancer: Studies have shown ivermectin can inhibit WNT pathway activity in colon cancer cells.
- Glioblastoma: In vitro experiments suggest anti-proliferative effects on glioblastoma stem cells.
- Leukemia: Ivermectin has demonstrated selectivity against certain leukemic cell lines in laboratory models.
- Ovarian and lung cancer: Preclinical models have shown dose-dependent growth inhibition.
A comprehensive 2021 analysis published in eClinicalMedicine (Lancet group) reviewed population-level cancer outcomes in regions with high ivermectin use and noted associations warranting further prospective investigation (PMC8248985).
It is important to emphasize that none of these preclinical findings constitute clinical evidence for using ivermectin as a cancer treatment. They represent early signals that justify further research.
Ivermectin in the Context of Drug Repurposing
Ivermectin is part of a broader trend in oncology called drug repurposing — investigating approved, well-characterized medications for new therapeutic applications. Other repurposed drugs being studied in cancer include fenbendazole, metformin, statins, and certain antifungals.
The appeal of repurposed drugs is practical: they already have known safety profiles, established manufacturing processes, and are often inexpensive. This makes them attractive candidates for combination therapies, especially in cancers with limited treatment options.
For a comparison of ivermectin with another commonly discussed antiparasitic, see: Fenbendazole vs. Ivermectin: Comparing Safety, Strength, and Effectiveness. You may also find relevant context in our overview of the Joe Tippens Protocol and the ISOM Protocol, both of which incorporate repurposed agents.
Safety Considerations
At approved antiparasitic doses, ivermectin has a well-established safety record spanning decades. Common side effects at standard doses include mild gastrointestinal discomfort, dizziness, and skin reactions (primarily related to parasite die-off in endemic infections).
However, the doses and schedules being explored in oncology research may differ from standard antiparasitic use. This is one of the key reasons clinical trials like NCT05318469 include dose-escalation phases — to carefully identify the safe therapeutic window when ivermectin is combined with potent immunotherapy agents.
For more on ivermectin dosing considerations, see: Safety-Focused Dosage Guide.
Self-prescribing ivermectin for cancer is not recommended. Any use outside approved indications should occur under medical supervision, ideally within a clinical trial framework.
Key Takeaways
- Ivermectin is a Nobel Prize-winning antiparasitic with a long safety history in approved uses.
- Preclinical research has identified multiple anti-tumor and immune-modulating mechanisms, but clinical evidence remains limited.
- The strongest current clinical interest is in combining ivermectin with immune checkpoint inhibitors, particularly in aggressive cancers like TNBC.
- NCT05318469 at Cedars-Sinai is the first structured Phase I/II trial testing ivermectin + immunotherapy in metastatic TNBC, with results expected by late 2026.
- Ivermectin remains an investigational agent in oncology — it is not an approved cancer treatment.
- Medical supervision is essential. Do not self-prescribe.
Disclaimer: This article is for educational and informational purposes only and does not constitute medical advice. Do not self-prescribe. Always consult a qualified oncologist or healthcare provider before making treatment decisions.
Scientific References
- Tang M, et al. (2020). Ivermectin, a potential anticancer drug derived from an antiparasitic drug. Pharmacological Research, 163, 105207. PMC7505114
- Draganov D, et al. (2021). Ivermectin converts cold tumors hot and synergizes with immune checkpoint blockade. Frontiers in Pharmacology. PMC8419571
- Guerini AE, et al. (2021). Ivermectin and cancer: An analysis of cancer incidence in populations using ivermectin. eClinicalMedicine (Lancet). PMC8248985
- ClinicalTrials.gov. NCT05318469: Ivermectin + Immunotherapy in Metastatic TNBC. NCT05318469
Protocol Stack (Quick Links)
Below are commonly referenced items mentioned in this article. Links are provided for convenience — always review the label and consult a professional before use.
6 / 12 / 18 mg — 100 tablets
Disclaimer: Links are informational and for convenience. This site does not provide medical advice and does not endorse any specific vendor. Always verify product quality, labeling, and consult a licensed professional for health decisions.
